BioSpace News Archive

Since we announced our investigation of impurities found in drugs known as angiotensin II receptor blockers, used to treat high blood pressure and heart failure, we’ve been working to thoroughly understand how this issue arose, how we could address and mitigate exposure to this unnecessary risk to patients, and what we could do to prevent these types of impurities from reoccurring in future medications.

HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending blood-based technology for evaluating the function of the liver, today announced the results from its proprietary HepQuant SHUNT™ Liver Diagnostic Kit in INTERCEPT’s placebo-controlled clinical trial of obeticholic acid (OCA), 747-117.

The Life Sciences division of AMPLEXOR, today announced release of AMPLEXOR VigilanceExpertTM 5.0, the latest update of its Life Sciences Suite of solutions that helps Life Sciences companies overcome challenges in Regulatory Affairs (RA), Research and Development (R&D), Quality Assurance/Quality Control (QA/QC), and Pharmacovigilance (PV).

New research recently published in the Journal of Pediatric Surgery found that post-operative success rates of pediatric thyroid patients, particularly children who require a thyroidectomy, correlate with the institution’s patient volume.

Global Genes®, a leading rare disease patient advocacy organization, in partnership with the Orphan Disease Center (ODC) in the Perelman School of Medicine at the University of Pennsylvania, is proud to announce the return of the Annual RARE Drug Development Symposium Friday, June 7, 2019, 9 a.m. — 5:30 p.m. at The Philadelphia 201 Hotel in Philadelphia

NASCAR driver Erik Jones is racing for more than a win at this Sunday’s Monster Energy NASCAR Cup Series race at Bristol Motor Speedway.

At this year’s AORN Global Surgical Conference & Expo in Nashville, Medline will launch its latest infection prevention innovations and community impact initiatives, including two perioperative solutions that address the pressing need of reducing hospital-acquired infections.

NanoCellect Biomedical Inc., a leader in the development and manufacture of solutions for cell-based assays, today announced a collaboration with the Parnassus Flow Cytometry Core facility at the University of California, San Francisco (UCSF).

To protect Canadian patients from the rare but serious risk of breast implant-associated anaplastic large cell lymphoma, Health Canada is advising Allergan that the Department intends to suspend its licences for Biocell breast implants as a precautionary measure.

The U.S. Food and Drug Administration is extending the indication of Ibrance capsules in combination with specific endocrine therapies for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in male patients.